

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: http://ees.elsevier.com/jot

ORIGINAL ARTICLE

Serum copper levels are associated with bone mineral density and total fracture



(2)

JOURNAL OF ORTHOPAEDIC

Xinhua Qu^{a,*}, Zihao He^{a,*}, Han Qiao^a, Zanjing Zhai^a, Zhenyang Mao^b, Zhifeng Yu^{a,**}, Kerong Dai^{a,*}

^a Department of Orthopedics, Shanghai Key Laboratory of Orthopedic Implant, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China
 ^b Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China

Received 3 May 2018; received in revised form 7 May 2018; accepted 8 May 2018 Available online 31 May 2018

KEYWORDS Bone mineral density; Fracture; Odds ratio; Serum copper levels	Abstract <i>Background:</i> Both copper deficiency and overexposure have been associated with adverse health effects. Evidence linking copper to bone mineral density (BMD) and total fracture, however, is limited. <i>Methods:</i> This nationally representative cross-sectional study enrolled participants from the National Health and Nutrition Examination Survey (2011–2014) in the United States. Using unadjusted and multivariate adjusted logistic regression analyses and a two-piecewise linear regression model with a smoothing function, we evaluated the associations between serum copper levels, bone mineral density and total fracture in 722 participants. <i>Results:</i> The study sample (n = 722, mean age: 56.47 ± 11.55 y) represented a population of which 47.2% were men; 43.91% were non-Hispanic white, 18.84% non-Hispanic black and 13.71% Mexican American; 25.9% had total fracture. In the multivariate logistic regression analysis, individuals in the lowest category (<98.5 μ g/dL) of serum copper concentration had 0.049 g/cm ² lower total femur BMD and 0.045 g/cm ² lower femoral neck BMD than those in the second concentration category (98.5–114 μ g/dL). Individuals in the highest category (>124 μ g/dL) of carrym copper in the second concentration category (98.5–114 μ g/dL).
	(\geq 134 µg/dL) of serum copper concentration had an approximately 4-fold increase in the

List of abbreviations: Bone mineral density, BMD; Confidence interval, CI; Centers for Disease Control and Prevention, CDC; Diastolic blood pressure, DBP; Dual-energy x-ray absorptiometry, DXA; High-density lipoprotein-cholesterol, HDL-C; National Center for Health Statistics, NCHS; Low-density lipoprotein-cholesterol, LDL-C; National Health and Nutrition Examination Survey, NHANES; Systolic blood pressure, SBP; Standard deviation, SD; Total cholesterol, TC; Triglycerides, TG.

* Corresponding author. Department of Orthopedics, Shanghai Key Laboratory of Orthopedic Implant, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.

** Corresponding author. Shanghai Key Laboratory of Orthopedic Implant, Department of Orthopedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.

E-mail addresses: zfyu@outlook.com (Z. Yu), krdai@163.com (K. Dai).

 \star XHQ and ZHH contributed equally to this study.

https://doi.org/10.1016/j.jot.2018.05.001

2214-031X/© 2018 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

risk of total fracture than those in the second concentration category. There were no significant associations between per 10 μ g/dL increases in serum copper levels and total fracture in multivariate logistic regression analysis after multivariate adjustment (all p > 0.05). However, a differential association between serum copper levels and total fractures between men and women was observed (odds ratio = 1.81, 95% confidence interval 1.08-3.03, p = 0.026 for men and odds ratio = 1.07, 95% confidence interval 0.86 -1.32, p = 0.552 for women).

Conclusion: Moderate serum copper levels are critically important for bone health. Lower serum copper levels are significantly associated with decreased BMD in the total femur and femoral neck. Higher serum copper levels are significantly associated with increased total fracture, especially in men.

The Translational Potential of this Article: The impact of serum copper concentrations on bone mineral density and total fracture can provide insights into clinical application of copper-containing supplements and biomaterials.

© 2018 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Copper is an essential trace element involved in many biological processes including enzymatic reactions, nucleic acid synthesis, antioxidant defence, iron metabolism and immune function. Copper deficiency may result in impaired bone and cholesterol metabolism and cardiovascular disorders [1,2]. Excessive copper has also been also associated with adverse health effects, including damaged lung, renal and liver function [1,3,4].

In recent years, owing to increased opportunities for exogenous copper uptake, people have become increasingly concerned about the health effects of copper exposure. For example, increasing copper-containing biomaterials have been developed. Biodegradable magnesium—copper or zinc—copper alloys [5—7] and copper-containing nanoparticles [8] have been researched and explored in the field of medical implants in recent years, especially for tissue engineering, cardiovascular, orthopaedic and antiinfective applications. Most copper-containing biomaterials were designed to be biodegradable and therefore release copper ions upon degradation. This may lead to increased levels of copper ions in the body.

Many epidemiological studies with mixed findings have investigated the associations between serum copper levels, cardiovascular disease and neurodegenerative diseases [9-12]. However, the association between copper status and the risk of osteoporosis and related diseases has been examined by only few observational studies and remains controversial because of inconsistent results [13-18]. Sadeghi et al. investigated the association between plasma copper and bone mineral density (BMD) in 135 Iranian women. They found that plasma copper and lead concentrations were higher in patients with low BMD than in control patients [18]. In another case-control study, the author did not find any statistically significant differences in serum copper concentrations among osteopenic, osteoporotic and control groups [17].

The studies mentioned above included a relatively small number of participants and thus might be underpowered to detect the associations between serum copper levels and BMD, and the impact of copper status on risk of fracture has not been assessed. Therefore, on the basis of the National Health and Nutrition Examination Survey (NHANES, 2011–2014), our study mainly evaluated the associations between serum copper levels, BMD and total fracture in the US population.

Materials and methods

Study population

We analysed data from NHANES 2011-2014, an independent cross-sectional study conducted by the Centers for Disease Control and Prevention and The National Center for Health Statistics designed to assess health and nutritional status in a nationally representative sample of noninstitutionalised, civilian general population in the United States. Survey details regarding plan, operation and design have been previously described [19-22]. Questionnaire surveys, physical examinations, household interviews including demographic, dietary, health-related questions and examinations and laboratory tests were performed. Our study population included both men and women aged 18 years and older, who were free from diabetes mellitus, rheumatoid arthritis or cancerous diseases and were not exposed to steroids. Three thousand six hundred eight individuals aged 18 years and older in the NHANES 2011-2014 were originally selected as our study sample, and after the exclusion process, 722 individuals were included in our final study sample for further analysis. The NHANES 2011-2014 was approved by the National Center for Health Statistics Ethics Review Board, and informed consent was obtained from all participants.

Measurement of serum copper concentrations

Serum copper concentrations were measured by inductively coupled plasma dynamic reaction cell mass spectrometry,

which is a multielement analytical technique capable of trace-level elemental analysis. Detailed instructions on specimen collection and processing can be found on the NHANES websites (https://wwwn.cdc.gov/Nchs/Nhanes/2011-2012/CUSEZN_G.htm and https://wwwn.cdc.gov/Nchs/Nhanes/2013-2014/CUSEZN_H.htm).

Assessments

Demographic data (age, sex and race), physical examination data [standing height (cm), weight (kg), body mass index (BMI, kg/m²), systolic blood pressure (mmHg), diastolic blood pressure (mmHg) and BMD (g/cm²)], laboratory data [serum lipids (mg/dL)] and questionnaire data [smoking status, alcohol consumption, activity status, fractures and major diseases, including cardiovascular disease (congestive heart failure, coronary heart disease and heart attack) and diabetes mellitus] were collected and are described on the NHANES websites at https://wwwn.cdc.gov/Nchs/Nhanes/continuousnhanes/default.aspx?BeginYear=2011 and https://wwwn.cdc.gov/Nchs/Nhanes/continuousnhanes/default.aspx?BeginYear=2013.

For all participants, race (Mexican American, Other Hispanic, Non-Hispanic white, Non-Hispanic black, other race), smoking status (yes or no), alcohol consumption (yes or no) and moderate physical activity (yes or no) were defined. BMD in the total spine, total femur and femoral neck were examined by dual-energy X-ray absorptiometry. Dual-energy X-ray absorptiometry scans were administered to eligible survey participants aged 40 years and older. The scans were acquired on Hologic QDR-4500A fan-beam densitometers (the radiation exposure: less than 20 uSv. Hologic, Inc., Bedford, Massachusetts) using software version Hologic APEX 3.2. All scans were analysed with Hologic APEX, version 4.0, software. Serum lipids, including total cholesterol (TC), triglycerides (TGs) and low-density lipoprotein-cholesterol (LDL-C) were analysed using the Roche Modular P chemistry analyser (enzymatic method). The whole blood glycohaemoglobin level was analysed using the Tosoh G8 glycohaemoglobin analyser.

Self-reported fractures were assessed via questionnaire. Prior low-trauma fractures were defined as self-reported fractures that occurred at an age >40 years due to a fall from a standing height or less, a trip/slip or a fall out of bed (hip, wrist and spine) or at an age >20 years not due to severe trauma such as a car accident or a hard fall down stairs or from a ladder (fractures other than hip, wrist and spine). Cardiovascular diseases were defined as congestive heart failure, coronary heart disease and heart attack. We defined subjects as having diabetes if they answered yes to the question: "Have you ever been told by a doctor that you have diabetes?" or the subject reported current use of insulin or an oral antihyperglycemic medication. Dyslipidaemia was defined as having high TG (\geq 200 mg/dL), TC $(\geq 240 \text{ mg/dL})$ and LDL-C $(\geq 160 \text{ mg/dL})$ or low high-density lipoprotein-cholesterol (HDL-C) (<40 mg/dL).

Statistical analysis

Continuous variables were presented as mean \pm standard deviation, while categorical variables were presented as

numbers and their proportion. We used the Chi-square tests for categorical variables, one-way analysis of variance for normally continuous variables and the Kruskal-Wallis test for skewed continuous variables. Regression coefficient and corresponding 95% confidence intervals (CI) were calculated using unadjusted and multivariate adjusted logistic regression analyses to determine associations between serum copper quartiles (<98.5 µg/dL, 98.5-114 µg/dL (ref.), 114 to 34 μ g/dL and >134 μ g/dL) or 10 μ g/dL increases in serum copper levels and BMD and total fracture. The crude model was adjusted for no variables. The multivariate model was adjusted for age, sex, race, BMI, smoking status, alcohol consumption, moderate physical activity, cardiovascular disease, dyslipidaemia, TG (mg/ dL), TC (mg/dL), HDL-C (mg/dL), LDL-C (mg/dL), serum selenium (μ g/L) and serum zinc (μ g/dL). We selected these confounders on the basis of their associations with the outcomes of interest or change in effect estimate of more than 10%. A two-sided p < 0.05 was considered statistically significant.

To examine the nonlinear association between serum copper levels, BMD and total fracture, we further applied a two-piecewise linear regression model using a smoothing function after adjusting for age, sex, race, BMI, smoking status, alcohol consumption, moderate physical activity, cardiovascular disease, dyslipidaemia, TG, TC, HDL-C, LDL-C, serum selenium and serum zinc. The threshold level was determined using trial and error, including selection of turning points along a predefined interval and then choosing the turning point that gave the maximum model likelihood. In addition, we conducted a log likelihood ratio test comparing the one-line linear regression model with the two-piecewise linear model. Statistical analyses were performed using R packages (http://www.r-project.org).

Results

Descriptive analysis

As shown in Table 1 and Figure 1, 722 subjects aged 18years or older were included in this study. For exposures of interest, serum copper concentrations (108 vs. 130 μ g/dL) were significantly lower in men than in women. For outcomes of interest, BMD in total femur (1.00 vs. 0.91 g/cm²), femoral neck (0.81 vs. 0.76 g/cm²) and total spine (1.02 vs. 0.99 g/cm²) was significantly higher in men than in women, whereas no significant association was found between total fracture and gender. The characteristics of our sample among serum copper quartiles are shown in Table 2. BMI and HDL-C were significantly associated with serum copper quartiles.

Serum copper levels and bone mineral density

Table 3 and Figure. 2A present the association between serum copper levels and BMD using the logistic regression and two-piecewise linear regression models. In the multivariate logistic regression analysis after multivariate adjustment for age, sex, race, BMI, smoking status, alcohol consumption, moderate physical activity, cardiovascular

Characteristic	Total number of particpa	ants (N = 722)	р
	Men	Women	
Number of participant	341	381	
Age (y)	$\textbf{56.59} \pm \textbf{11.37}$	56.36 ± 11.71	0.785
Weight (kg)	$\textbf{84.45} \pm \textbf{18.40}$	$\textbf{75.20} \pm \textbf{20.43}$	<0.001
Standing height (cm)	172.93 ± 7.52	$\textbf{160.40} \pm \textbf{6.96}$	<0.001
Body mass index (kg/m ²)	$\textbf{28.18} \pm \textbf{5.53}$	$\textbf{29.19} \pm \textbf{7.38}$	0.186
Systolic blood pressure (mmHg)	126.78 ± 17.63	125.35 ± 19.41	0.318
Diastolic blood pressure (mmHg)	$\textbf{72.19} \pm \textbf{13.14}$	$\textbf{70.37} \pm \textbf{13.08}$	0.026
Serum copper (ug/dL)	$\textbf{108.42} \pm \textbf{19.69}$	130.52 ± 25.43	<0.001
Serum selenium (ug/L)	133.52 ± 18.46	129.33 ± 18.89	0.003
Serum zinc (ug/dL)	$\textbf{81.80} \pm \textbf{15.87}$	$\textbf{80.44} \pm \textbf{14.47}$	0.230
Serum lipids			
Total cholesterol	195.55 ± 42.49	$\textbf{200.83} \pm \textbf{41.12}$	0.091
Triglyceride	132.26 ± 90.14	102.13 ± 52.18	<0.001
HDL-cholesterol	50.11 ± 15.91	$\textbf{60.29} \pm \textbf{15.62}$	<0.001
LDL-cholesterol	$\textbf{120.27} \pm \textbf{39.69}$	120.55 ± 39.21	0.946
Bone mineral density (g/cm ²)			
Total femur	1.00 ± 0.14	$\textbf{0.91} \pm \textbf{0.15}$	<0.001
Femoral neck	$\textbf{0.81} \pm \textbf{0.14}$	$\textbf{0.76} \pm \textbf{0.15}$	<0.001
Total spine	$\textbf{1.02} \pm \textbf{0.16}$	$\textbf{0.99} \pm \textbf{0.16}$	0.048
Race			0.512
Mexican American	51 (14.96%)	48 (12.60%)	
Other Hispanic	27 (7.92%)	43 (11.29%)	
Non-Hispanic white	151 (44.28%)	166 (43.57%)	
Non-Hispanic black	67 (19.65%)	69 (18.11%)	
Other race	45 (13.20%)	55 (14.44%)	
Total fracture			0.775
No	251 (73.61%)	284 (74.54%)	
Yes	90 (26.39%)	97 (25.46%)	
Cardiovascular diseases			0.035
No	314 (92.08%)	365 (95.80%)	
Yes	27 (7.92%)	16 (4.20%)	
Dyslipidaemia			<0.001
No	210 (61.58%)	302 (79.27%)	
Yes	131 (38.42%)	79 (20.73%)	
Smoking status			<0.001
Yes	189 (55.43%)	136 (35.70%)	
No	152 (44.57%)	245 (64.30%)	
Alcohol drinking			<0.001
Yes	261 (84.74%)	219 (62.57%)	
No	47 (15.26%)	131 (37.43%)	
Moderate work activity			0.070
Yes	106 (31.27%)	96 (25.20%)	
No	233 (68.73%)	285 (74.80%)	

HDL = high-density lipoprotein; LDL = low-density lipoprotein; NHANES = National Health and Nutrition Examination Survey; SD = standard deviation.

Values are mean \pm SD or n (%).

disease, dyslipidaemia, TG, TC, HDL-C, LDL-C, serum selenium and serum zinc, individuals in the lowest category (<98.5 μ g/dL) of serum copper concentration had 0.049 g/ cm² lower total femur BMD and 0.045 g/cm² lower femoral neck BMD compared to those in the second concentration category (98.5–114 μ g/dL). However, there were no significant linear associations between per 10 μ g/dL increases in serum copper levels and all site BMD in multivariate

logistic regression analysis after multivariate adjustment (all p > 0.05).

Serum copper levels and total fractures

Table 4 and Figure. 2B and C present the association between serum copper levels and total fractures. In the



Figure 1 Study sample selection flowchart.

BMD = bone mineral density; NHANES = NHANES = National Health and Nutrition Examination Survey.

multivariate logistic regression analysis, after being adjusted for age, sex, race, BMI, smoking status, alcohol consumption, moderate physical activity, cardiovascular disease, dyslipidaemia, TG, TC, HDL-C, LDL-C, serum selenium, serum zinc, total spine BMD and total femur BMD, individuals in the highest category (\geq 134 µg/dL) of serum copper concentration had an approximately 4-fold increase in risk of total fracture compared to those in the second concentration category (98.5–114 µg/dL). However, there were no significant linear associations between per 10 µg/dL increases in serum copper levels and total fracture in multivariate logistic regression analysis after multivariate adjustment (p = 0.303).

Stratified analysis of the association between serum copper levels and BMD and total fractures for gender and age

We examined whether gender and age affected the association between serum copper levels, BMD and total fractures. As shown in Table 5, we observed a differential association between serum copper levels and total fractures between men and women after being adjusted for age, race, BMI, smoking status, alcohol consumption, moderate physical activity, cardiovascular disease, dyslipidaemia, TG, TC, HDL-C, LDL-C, serum selenium, serum zinc, total spine BMD and total femur BMD (odds ratio = 1.81, 95% CI 1.08, 3.03, p = 0.026 for men and odds ratio = 1.07, 95% CI 0.86, 1.32, p = 0.552 for women). Moreover, a significant interactive effect was detected (*P* for interaction = 0.045).

As shown in Table 6, there was no differential association between serum copper levels and total femur, femoral neck and total spine BMD among groups aged <50y, 50-65y and >65y after multivariate adjustment. Moreover, there were no significant interactive effects of age on the associations between serum copper levels and BMDs. (all *P* for interaction >0.05) However, a significant interactive effect of age on the associations between serum copper levels and total fracture was detected (*P* for interaction = 0.0005).

 Table 2
 Characteristics of study sample among serum copper quartiles.

Characteristic	Serum copper (ug/dL)					
	<98.5	98.5 to 114	114 to 34	≥134		
Number of participants	142	184	214	182		
Age (y)	$\textbf{54.95} \pm \textbf{11.03}$	$\textbf{57.83} \pm \textbf{11.85}$	$\textbf{56.82} \pm \textbf{11.26}$	$\textbf{55.86} \pm \textbf{11.88}$	0.127	
Weight (kg)	$\textbf{79.17} \pm \textbf{18.25}$	$\textbf{77.55} \pm \textbf{16.97}$	$\textbf{78.79} \pm \textbf{21.10}$	$\textbf{82.91} \pm \textbf{22.52}$	0.065	
Standing height (cm)	$\textbf{170.85} \pm \textbf{8.67}$	168.31 ± 10.09	$\textbf{165.06} \pm \textbf{9.17}$	$\textbf{162.29} \pm \textbf{8.09}$	<0.001	
Body mass index (kg/m ²)	$\textbf{26.99} \pm \textbf{5.18}$	$\textbf{27.26} \pm \textbf{4.77}$	$\textbf{28.78} \pm \textbf{6.75}$	$\textbf{31.44} \pm \textbf{7.95}$	<0.001	
Systolic blood pressure (mmHg)	$\textbf{124.23} \pm \textbf{16.77}$	124.56 ± 16.90	$\textbf{126.80} \pm \textbf{19.46}$	$\textbf{128.00} \pm \textbf{20.35}$	0.205	
Diastolic blood pressure (mmHg)	$\textbf{73.31} \pm \textbf{10.34}$	$\textbf{71.21} \pm \textbf{13.33}$	$\textbf{70.21} \pm \textbf{13.38}$	70.85 ± 14.44	0.195	
Serum selenium (ug/L)	132.18 ± 18.11	$\textbf{132.47} \pm \textbf{19.08}$	$\textbf{130.27} \pm \textbf{19.35}$	130.67 ± 18.41	0.603	
Serum zinc (ug/dL)	$\textbf{80.14} \pm \textbf{17.20}$	$\textbf{81.16} \pm \textbf{13.62}$	$\textbf{80.06} \pm \textbf{14.93}$	$\textbf{82.95} \pm \textbf{15.12}$	0.233	
Serum lipids (mg/dL)						
Total cholesterol	$\textbf{192.24} \pm \textbf{42.30}$	198.31 ± 41.74	$\textbf{198.82} \pm \textbf{43.14}$	$\textbf{202.56} \pm \textbf{39.68}$	0.182	
Triglyceride	$\textbf{130.94} \pm \textbf{96.70}$	116.51 ± 86.87	113.06 ± 61.34	108.25 ± 50.06	0.221	
HDL-cholesterol	52.91 \pm 15.83	$\textbf{54.84} \pm \textbf{17.92}$	54.76 ± 13.51	$\textbf{59.02} \pm \textbf{18.38}$	0.006	
LDL-cholesterol	113.57 ± 37.05	116.74 ± 37.16	127.00 ± 44.29	121.83 ± 36.78	0.115	
Bone mineral density (g/cm^2)						
Total femur	0.95 ± 0.14	0.97 ± 0.16	$\textbf{0.93} \pm \textbf{0.15}$	0.96 ± 0.15	0.123	
Femoral neck	0.77 ± 0.13	0.80 ± 0.15	0.78 ± 0.14	0.81 ± 0.15	0.086	
Total spine	$\textbf{1.00} \pm \textbf{0.13}$	0.99 ± 0.17	$\textbf{1.01} \pm \textbf{0.16}$	$\textbf{1.03} \pm \textbf{0.15}$	0.288	
Sex					<0.001	
Man	111 (78.17%)	116 (63.04%)	85 (39.72%)	29 (15.93%)		
Woman	31 (21.83%)	68 (36.96%)	129 (60.28%)	153 (84.07%)		
Race	(, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	<0.001	
Mexican American	20 (14.08%)	21 (11.41%)	28 (13.08%)	30 (16.48%)		
Other Hispanic	11 (7.75%)	17 (9.24%)	22 (10.28%)	20 (10.99%)		
Non-Hispanic white	68 (47.89%)	87 (47.28%)	91 (42.52%)	71 (39.01%)		
Non-Hispanic black	10 (7.04%)	25 (13.59%)	51 (23.83%)	50 (27.47%)		
Other race	33 (23.24%)	34 (18.48%)	22 (10.28%)	11 (6.04%)		
Total fracture	(· · · ·	· · · ·	· · · ·	0.974	
No	104 (73.24%)	136 (73.91%)	161 (75.23%)	134 (73.63%)		
Yes	38 (26.76%)	48 (26.09%)	53 (24.77%) [´]	48 (26.37%)		
Cardiovascular diseases	(· · · ·	· · · ·	· · · ·	0.112	
No	138 (97.18%)	171 (92.93%)	196 (91.59%)	174 (95.60%)		
Yes	4 (2.82%)	13 (7.07%)	18 (8.41%)	8 (4.40%)		
Dyslipidaemia					0.257	
No	95 (66.90%)	124 (67.39%)	158 (73.83%)	135 (74.18%)		
Yes	47 (33.10%)	60 (32.61%)	56 (26.17%) [´]	47 (25.82%)		
Smoking	, , , , , , , , , , , , , , , , , , ,	· · ·	· · · ·	· · ·	0.693	
Yes	60 (42.25%)	80 (43.48%)	103 (48.13%)	82 (45.05%)		
No	82 (57.75%)	104 (56.52%)	111 (51.87%)	100 (54.95%)		
Alcohol drinking	(· · · ·	· · · ·	· · · ·	0.025	
Yes	100 (77.52%)	128 (78.05%)	144 (72.73%)	108 (64.67%)		
No	29 (22.48%)	36 (21.95%)	54 (27.27%)	59 (35.33%)		
Moderate physical activity		((,	0.451	
Yes	38 (26.95%)	53 (28.96%)	67 (31.31%)	44 (24.18%)		
No	103 (73.05%)	130 (71.04%)	147 (68.69%)	138 (75.82%)		
				(/		

HDL = high-density lipoprotein; LDL = low-density lipoprotein; SD = standard deviation.

Values are mean \pm SD or n (%).

Discussion

In recent years, biodegradable copper-containing biomaterials have been researched and explored in the field of medical implants. Because of increased opportunities for exogenous copper uptake, people are more concerned about the health effects of exposure to copper. Therefore, investigating the relationship between serum copper levels and bone health can lay a foundation for future design, application, contraindications and postimplantation strategies for copper-containing biomaterials, most notably for orthopaedic biomaterials [23]. This study analysed the data of 722 participants from the NHANES (2011–2014) and found that individuals in the lowest category (<98.5 μ g/dL)

	Unadjusted model		Adjusted model		
	β (95% CI)	р	β (95% CI)	р	
Total femur BMD (g/cm ²)					
Serum copper (ug/dL)					
<98.5	-0.019 (-0.053, 0.015)	0.27460	-0.049 (-0.091, -0.007)	0.02264	
98.5 to 114	0 (ref.)		0 (ref.)		
114 to 34	-0.037 (-0.068, -0.005)	0.02143	-0.039 (-0.080, 0.003)	0.06773	
≥134	-0.010 (-0.043, 0.023)	0.56254	-0.028 (-0.074, 0.018)	0.23504	
Per 10 ug/dL increased in serum copper	-0.000 (-0.005, 0.004)	0.84804	0.003 (-0.003, 0.010)	0.31590	
Femoral neck BMD (g/cm ²)					
Serum copper (ug/dL)					
<98.5	-0.024 (-0.057, 0.008)	0.14456	-0.056 (-0.097, -0.015)	0.00783	
98.5 to 114	0 (ref.)		0 (ref.)		
114 to 34	-0.021 (-0.050, 0.009)	0.16653	-0.045 (-0.085, -0.004)	0.03041	
≥134	0.011 (-0.020, 0.043)	0.47146	-0.041 (-0.086, 0.005)	0.07972	
Per 10 ug/dL increased in serum copper	0.003 (-0.002, 0.007)	0.20775	0.001 (-0.005, 0.007)	0.81142	
Total spine BMD (g/cm ²)					
Serum copper (ug/dL)					
<98.5	0.004 (-0.039, 0.047)	0.85799	-0.028 (-0.091, 0.035)	0.38230	
98.5 to 114	0 (ref.)		0 (ref.)		
114 to 34	0.019 (-0.019, 0.057)	0.33073	0.011 (-0.054, 0.077)	0.73234	
≥134	0.036 (-0.003, 0.076)	0.07440	-0.018 (-0.089, 0.053)	0.61736	
Per 10 ug/dL increased in serum copper	0.004 (-0.002, 0.010)	0.16410	-0.002 (-0.011, 0.008)	0.72430	

 Table 3
 Associations between serum copper levels and BMDs.

BMD = bone mineral density; CI = confidence interval; HDL = high-density lipoprotein; LDL = low-density lipoprotein. β regression coefficient. Adjust for: age; sex; race; body mass index (kg/m²); smoking statues; alcohol drinking; moderate physical activity; cardiovascular diseases; dyslipidaemia; triglyceride (mg/dL), total cholesterol(mg/dL); HDL-cholesterol (mg/dL); LDL-cholesterol (mg/dL); serum selenium (ug/L); serum zinc (ug/dL).

of serum copper concentration had 0.049 g/cm² lower total femur BMD and 0.045 g/cm² lower femoral neck BMD compared to those in the second concentration category (98.5–114 µg/dL). Individuals in the highest category (\geq 134 µg/dL) of serum copper concentration had an approximately 4-fold increase in risk of total fracture compared to those in the second concentration category. Moreover, there was a significant linear association between per 10 µg/dL increases in serum copper levels and total fracture in men.

Many studies have shown that copper ions are necessary for the health of bone tissue [24,25]. Our study found that low concentrations of serum copper lead to lower BMD, whereas higher serum copper levels are associated with an increased risk of fracture. Under physiological conditions, copper ions could induce a hypoxic microenvironment such as hypoxia mimicking ions and an increase in BMD by promoting the expression of bone-related genes (ALP, OPN, OPN). This may inhibit active bone resorption and can enhance angiogenesis by promoting the expression of vascular endothelial growth factor [26-28]. In addition, the activity of lysyl oxidase, which is necessary for covalent cross-linking of collagen, is dependent on copper ions. Collagen is the main component of bone tissue extracellular matrix, and the integrity of bone matrix is very important to the strength and plastic deformation of bone, meaning copper can affect the formation of extracellular matrix of bone tissue [29-31]. Copper can also promote both osteogenesis and adipogenic differentiation of bone mesenchymal stem cells (BMSC), but gives priority to the differentiation of the osteogenic lineage [30]. Therefore, the lack of copper ions will harm the bone tissue, lead to the enhancement of bone resorption and the disorder of lysyl oxidase [32], decrease cancellous bone, weaken bone formation and mineralisation, impair cartilage integrity and eventually reduce bone density. In animal experiments, copper deficiency has been found to lead to bone deformities, hypoplasia, fragile bones and frequent fractures. Less loss of axial and peripheral bone mass has been found in ovariectomy-induced reduction of bone mass in rats supplemented with copper, and it is suggested that copper has therapeutic potential in osteoporosis [33]. A decrease in bone mass due to copper deficiency has also been observed in goats [34]. In epidemiological studies, serum copper levels in patients with osteoporosis, lumbar osteopenia and femoral neck fracture were lower than those in the normal group, and low serum copper levels were also considered as a risk factor for age-related osteoporosis. Some even suggested that copper could be used as a simple radiation-free screening method for osteoporosis. In terms of diet, a low-copper diet is thought to be associated with osteoporosis and ischaemic heart disease, and adequate dietary copper intake is important for maintaining healthy bone and cartilage [35–37].

On the other hand, the harm caused by excessive copper levels has also been studied. For example, copper has direct toxicity to cartilage and bone in chicken embryo bone tissue [38], and an abundance of serum copper has been found to cause a decrease in bone size and bone density in C57 mice [39]. It was also found that copper



Figure 2 (A) Multivariate adjusted smoothing spline plots of serum copper levels and bone mineral density; (B and C) multivariate adjusted smoothing spline plots of serum copper levels and fractures. Model 1 (A and B) is adjusted for age, sex, race, BMI, smoking status, alcohol consumption, moderate physical activity, cardiovascular disease, dyslipidaemia; triglyceride (mg/dL), total cholesterol (mg/dL), HDL-cholesterol (mg/dL), LDL-cholesterol (mg/dL), serum selenium (μ g/L) and serum zinc (μ g/dL). Model 2 (C) is adjusted for model 1 plus total spine BMD and total femur BMD. The red line represents the line of best-fit, and the blue lines are 95% confidence intervals.

BMD = bone mineral density; HDL = high-density lipoprotein; LDL = low-density lipoprotein

	Unadjusted model		Adjusted model		Adjusted model plus BMD ^a	
	OR (95% CI)	р	OR (95% CI)	р	OR (95% CI)	р
Serum copper (ug/dL)						
<98.5	1.035 (0.630, 1.701)	0.89116	1.767 (0.686, 4.550)	0.23805	2.128 (0.610, 7.430)	0.23641
98.5 to 114	1.0 (ref.)		1.0 (ref.)		1.0 (ref.)	
114 to 34	0.933 (0.593, 1.466)	0.76279	2.554 (1.061, 6.147)	0.03645	3.555 (1.055, 11.975)	0.04071
≥134	1.015 (0.637, 1.617)	0.95029	3.358 (1.280, 8.810)	0.01381	4.225 (1.148, 15.558)	0.03023
Per 10 ug/dL increased	0.977 (0.914, 1.043)	0.48292	1.081 (0.956, 1.223)	0.21360	1.087 (0.927, 1.274)	0.30336
in serum copper						
	situu Classofidanaa int		litely devices the devices the		laur dan situ lin an ustain. C	\r

Table 4	Associations	between	serum copper	level	s and	total	fracture
---------	--------------	---------	--------------	-------	-------	-------	----------

BMD = bone mineral density; CI = confidence interval; HDL = high-density lipoprotein; LDL = low-density lipoprotein; OR = odds ratio.

Adjust for: age; sex; race; body mass index (kg/m²); smoking statues; alcohol drinking; moderate physical activity; cardiovascular diseases; dyslipidaemia; triglyceride (mg/dL), total cholesterol(mg/dL); HDL-cholesterol (mg/dL); LDL-cholesterol (mg/dL); serum selenium (ug/L); serum zinc (ug/dL).

^a Adjusted model plus total spine BMD; total femur BMD.

could inhibit *in vitro* osteogenic differentiation of transcription factors such as Runx2 by inducing a hypoxic microenvironment. This thereby regulates the differentiation of rat BMSC, inhibiting osteogenic differentiation, promoting adipogenic differentiation and inhibiting cytoskeletal changes [40]. The apoptosis of BMSC was induced with an increase in copper concentration [41]. Excessive copper also produces large amounts of free radicals that cause lipid peroxidation and interfere with bone metabolism, leading to a decrease in bone cortex and bone

	Men		Women	P for interaction	
	β/ OR (95% CI)	р	β/OR (95% CI)	р	
Total femur BMD (g/cm ²)					
Unadjusted model	0.005 (-0.003, 0.013)	0.2033	0.012 (0.005, 0.018)	0.0005	0.1976
Adjusted model	0.000 (-0.011, 0.011)	0.9837	0.003 (-0.004, 0.010)	0.3560	0.5962
Femoral neck BMD (g/cm2)					
Unadjusted model	0.005 (-0.003, 0.012)	0.2164	0.011 (0.005, 0.018)	0.0006	0.2009
Adjusted model	-0.005 (-0.016, 0.006)	0.3498	0.002 (-0.005, 0.009)	0.4913	0.2021
Total spine BMD (g/cm2)					
Unadjusted model	0.011 (-0.000, 0.022)	0.0571	0.008 (-0.000, 0.015)	0.0630	0.6267
Adjusted model	0.006 (-0.013, 0.025)	0.5360	-0.004 (-0.014, 0.007)	0.4664	0.3087
Total fracture					
Unadjusted model	0.965 (0.852, 1.092)	0.5709	0.982 (0.897, 1.076)	0.7045	0.8163
Adjusted model	1.308 (1.025, 1.670)	0.0312	1.016 (0.857, 1.206)	0.8534	0.1592
Adjusted model plus BMD ^a	1.805 (1.075, 3.029)	0.0255	1.066 (0.863, 1.317)	0.5521	0.0452

 Table 5
 Effect of sex on the associations between serum copper levels (Per 10 ug/dL increased in serum copper) and BMDs and fracture.

BMD = bone mineral density; CI = confidence interval; HDL = high-density lipoprotein; LDL = low-density lipoprotein; OR = odds ratio.

 β regression coefficient. Adjust for: age; race; body mass index (kg/m2); smoking status; alcohol drinking; moderate physical activity; cardiovascular diseases; dyslipidaemia; triglyceride (mg/dL), total cholesterol(mg/dL); HDL-cholesterol (mg/dL); LDL-cholesterol (mg/dL); serum selenium (ug/L); serum zinc (ug/dL).

^a Adjusted model plus total spine BMD; total femur BMD.

Table 6 Effect of age on the associations between serum copper levels (Per 10 ug/dL increased in serum copper) and BMDs and fracture.

	<50 y		50 to 65 y		≥65 y	P for	
	β/ OR (95% CI)	р	β/ OR (95% CI)	р	β/ OR (95% CI)	р	interaction
Total femur E	BMD (g/cm ²)						
Unadjusted model	0.005 (-0.002, 0.012)	0.1550	-0.001 (-0.007, 0.006)	0.8528	-0.010 (-0.022, 0.001)	0.0875	0.0584
Adjusted model	0.005 (-0.005, 0.016)	0.3141	0.002 (-0.007, 0.011)	0.7039	-0.011 (-0.027, 0.005)	0.1944	0.1139
Femoral neck	x BMD (g/cm ²)						
Unadjusted model	0.008 (0.002, 0.015)	0.0149	0.002 (-0.004, 0.009)	0.4695	-0.007 (-0.017, 0.004)	0.2182	0.0426
Adjusted model	-0.001 (-0.012, 0.010)	0.8804	-0.001 (-0.010, 0.008)	0.7660	-0.013 (-0.029, 0.002)	0.0997	0.2206
Total spine B	MD (g/cm2)						
Unadjusted model	0.008 (0.002, 0.015)	0.0171	0.002 (-0.007, 0.011)	0.6848	-0.008 (-0.027, 0.011)	0.4046	0.1264
Adjusted model	0.001 (-0.012, 0.014)	0.8410	-0.003 (-0.018, 0.012)	0.7299	-0.021 (-0.060, 0.017)	0.2966	0.2312
Total fracture	9						
Unadjusted model	0.970 (0.865, 1.089)	0.6107	0.890 (0.801, 0.989)	0.0300	1.168 (1.015, 1.344)	0.0298	0.0085
Adjusted model	1.012 (0.767, 1.334)	0.9343	0.855 (0.679, 1.078)	0.1851	1.35 ^a (0.996, 1.838)	0.0527	0.0005
Adjusted model plus BMD ^a	0.989 (0.725, 1.347)	0.9420	0.881 (0.604, 1.284)	0.5097	NA	NA	NA

BMD = bone mineral density; CI = confidence interval; HDL = high-density lipoprotein; LDL = low-density lipoprotein; OR = odds ratio.

 β regression coefficient. Adjust for: sex; race; body mass index (kg/m²); smoking status; alcohol drinking; moderate physical activity; cardiovascular diseases; dyslipidaemia; triglyceride (mg/dL), total cholesterol(mg/dL); HDL-cholesterol (mg/dL); LDL-cholesterol (mg/dL); serum selenium (ug/L); serum zinc (ug/dL).

^a Adjusted model plus total spine BMD; total femur BMD

strength. Oxidation can also, in itself, promote ageing and reduce bone strength [42–45]. In Wilson's disease, characterised by copper deposition, epidemiological studies show that the BMD of cortical and cancellous bone are normal, whereas the risk of fracture is increased. As BMD does not evaluate bone microstructure, there may be a decrease in bone strength after excluding factors such as mental state, low BMI and amenorrhea. In addition, excessive copper and decreased bone strength are also associated with other disease manifestations such as rickets and abnormal osteophytes [43,46]. These findings are also consistent with the increase in fractures we observed at high serum copper concentrations.

Only few observational studies with mixed findings have investigated the associations between serum copper levels and BMD [13–18]. However, most of these studies were based on patients in hospital, which suggests that their findings might be biased towards unhealthy individuals and therefore cannot be extrapolated to the general population. Additionally, no previous studies have validated the relationship between copper status and fracture. Our research, using a large nationally representative sample of adults in the United States, is the largest cross-sectional study to evaluate the associations between serum copper levels and BMD and fracture.

There were several limitations in this study. First, because of the cross-sectional nature of the study, causal relationships between serum copper levels, BMD and fracture cannot be detected. Second, as an inherent characteristic of cross-sectional studies, some biases are inherent although we tried to minimise these biases using a variety of procedures. Third, risk of BMD and fractures are associated with many factors, such as lifestyle, disease status, metabolic factors and genetic factors. Several fracture risk prediction tools have been developed using different risk factors. Age, BMI, rheumatoid arthritis, smoking status and alcohol status are the most common risk factors. Although wide variables were included in the adjustment, we could not exclude the possibility of residual confounding variables in the analyses, such as serum calcium, phosphorus and vitamin D. Therefore, further stratified cohort studies that include sufficient controls and account for confounding factors are, therefore, needed to elucidate the link between serum copper level and the risk of BMD and fracture.

In conclusion, our study demonstrates that lower serum copper levels are significantly associated with decreased BMD in the total femur and femoral neck. Higher serum copper levels are significantly associated with increased total fracture, especially in men. Moderate serum copper levels are vital for bone health. Prospective cohort studies are still warranted to confirm these findings.

Authors' contributions

XHQ, ZFY and KRD were responsible for the initial plan, study design, data collection, data interpretation, manuscript drafting, statistical analysis and conducting the study. ZHH was responsible for statistical analysis and critical revisions of the manuscript. HQ, ZJJ and ZYM were responsible for critical revisions of the manuscript. This article's contents are solely the responsibility of the authors. ZFY and KRD are the guarantors for this article and have full responsibility for this study. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare that they have no competing interests.

Acknowledgements/Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 51631009, 11572197 and 81401852), "Chen Guang" Project of the Shanghai Municipal Education Commission, Shanghai Education Development Foundation (No. 14CG14).

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jot.2018.05.001.

References

- Bost M, Houdart S, Oberli M, Kalonji E, Huneau JF, Margaritis I. Dietary copper and human health: current evidence and unresolved issues. J Trace Elem Med Biol 2016;35:107–15.
- [2] Klevay LM. IHD from copper deficiency: a unified theory. Nutr Res Rev 2016;29(2):172-9.
- [3] Esfahani ST, Hamidian MR, Madani A, Ataei N, Mohseni P, Roudbari M, et al. Serum zinc and copper levels in children with chronic renal failure. Pediatr Nephrol 2006;21(8): 1153-6.
- [4] Skoczynska A, Gruszczynski L, Wojakowska A, Scieszka M, Turczyn B, Schmidt E. Association between the type of workplace and lung function in copper miners. Biomed Res Int 2016;2016:5928572.
- [5] Tang Z, Niu J, Huang H, Zhang H, Pei J, Ou J, et al. Potential biodegradable Zn-Cu binary alloys developed for cardiovascular implant applications. J Mech Behav Biomed Mater 2017; 72:182–91.
- [6] Li Y, Liu L, Wan P, Zhai Z, Mao Z, Ouyang Z, et al. Biodegradable Mg-Cu alloy implants with antibacterial activity for the treatment of osteomyelitis: *in vitro* and *in vivo* evaluations. Biomaterials 2016;106:250–63.
- [7] Chen X. Magnesium-based implants: beyond fixators. J Orthop Translat 2017;10:1-4.
- [8] Gao W, Sun Y, Cai M, Zhao Y, Cao W, Liu Z, et al. Copper sulfide nanoparticles as a photothermal switch for TRPV1 signaling to attenuate atherosclerosis. Nat Commun 2018;9(1):231.
- [9] Zang X, Huang H, Zhuang Z, Chen R, Xie Z, Xu C, et al. The association between serum copper concentrations and cardiovascular disease risk factors in children and adolescents in NHANES. Environ Sci Pollut Res Int 2018 Apr 6. https: //doi.org/10.1007/s11356-018-1816-6. [Epub ahead of print].
- [10] Chen A, Li G, Liu Y. Association between copper levels and myocardial infarction: a meta-analysis. Inhal Toxicol 2015; 27(5):237–46.
- [11] Pal A, Kumar A, Prasad R. Predictive association of copper metabolism proteins with Alzheimer's disease and Parkinson's disease: a preliminary perspective. Biometals An Int J Role Metal Ions Biol Biochem Med 2014;27(1):25–31.

- [12] Arnal N, Morel GR, de Alaniz MJ, Castillo O, Marra CA. Role of copper and cholesterol association in the neurodegenerative process. Int J Alzheimers Dis 2013;2013:414817.
- [13] Mahdavi-Roshan M, Ebrahimi M, Ebrahimi A. Copper, magnesium, zinc and calcium status in osteopenic and osteoporotic post-menopausal women. Clin Cases Miner Bone Metab 2015; 12(1):18-21.
- [14] Razmandeh R, Nasli-Esfahani E, Heydarpour R, Faridbod F, Ganjali MR, Norouzi P, et al. Association of Zinc, Copper and Magnesium with bone mineral density in Iranian postmenopausal women - a case control study. J Diabetes Metab Disord 2014;13(1):43.
- [15] Nielsen FH, Lukaski HC, Johnson LK, Roughead ZK. Reported zinc, but not copper, intakes influence whole-body bone density, mineral content and T score responses to zinc and copper supplementation in healthy postmenopausal women. Br J Nutr 2011;106(12):1872–9.
- [16] Chaudhri MA, Kemmler W, Harsch I, Watling RJ. Plasma copper and bone mineral density in osteopenia: an indicator of bone mineral density in osteopenic females. Biol Trace Elem Res 2009;129(1–3):94–8.
- [17] Mutlu M, Argun M, Kilic E, Saraymen R, Yazar S. Magnesium, zinc and copper status in osteoporotic, osteopenic and normal post-menopausal women. J Int Med Res 2007;35(5): 692-5.
- [18] Sadeghi N, Oveisi MR, Jannat B, Hajimahmoodi M, Behzad M, Behfar A, et al. The relationship between bone health and plasma zinc, copper lead and cadmium concentration in osteoporotic women. J Environ Health Sci Eng 2014;12(1): 125.
- [19] Wu C, Woo JG, Zhang N. Association between urinary manganese and blood pressure: results from national health and nutrition examination survey (NHANES), 2011–2014. PLoS One 2017;12(11). e0188145.
- [20] Ostchega Y, Zhang G, Kit BK, Nwankwo T. Factors associated with home blood pressure monitoring among US adults: national health and nutrition examination survey, 2011–2014. Am J Hypertens 2017;30(11):1126–32.
- [21] Liu EW, Chastain HM, Shin SH, Wiegand RE, Kruszon-Moran D, Handali S, et al. Seroprevalence of antibodies to Toxocara species in the United States and associated risk factors, 2011–2014. Clin Infect Dis 2018;66(2):206–12.
- [22] Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 2017; 40(11):1425-32.
- [23] Chen CH, O'Keefe R. Clinical translation and application in orthopaedics. J Orthop Translat 2018;12:A3-4.
- [24] Rondanelli M, Opizzi A, Perna S, Faliva MA. Update on nutrients involved in maintaining healthy bone. Endocrinología y Nutrición 2013;60(4):197–210.
- [25] Aaseth J, Boivin G, Andersen O. Osteoporosis and trace elements – an overview. J Trace Elem Med Biol 2012;26(2): 149–52.
- [26] Mir E, Hosseinnezhad A, Bahrami A, Bekheirnia MR. Adequate serum copper concentration could improve bone density, postpone bone loss and protect osteoporosis in women. Iran J Public Health 2007;36(2):24–9.
- [27] Bari A, Bloise N, Fiorilli S, Novajra G, Vallet-Regí M, Bruni G, et al. Copper-containing mesoporous bioactive glass nanoparticles as multifunctional agent for bone regeneration. Acta Biomaterialia 2017;55:493–504.

- [28] Wilson T, Katz JM, Gray DH. Inhibition of active bone resorption by copper. Calcif Tissue Int 1981;33(1):35–9.
- [29] Ettinger S. Chapter 9-osteoporosis and fracture risk. In: Nutritional pathophysiology of obesity and its comorbidities. Academic Press; 2017. p. 209–34.
- [30] Rodríguez JP, Ríos S, González M. Modulation of the proliferation and differentiation of human mesenchymal stem cells by copper. J Cell Biochem 2002;85(1):92–100.
- [31] Opsahl W, Zeronian H, Ellison M, Lewis D, Rucker RB, Riggins RS. Role of copper in collagen cross-linking and its influence on selected mechanical properties of chick bone and tendon. J Nutr 1982;112(4):708–16.
- [32] Sarazin M, Alexandre C, Thomas T. Influence of trace element, protein, lipid, carbohydrate, and vitamin intakes on bone metabolism. Revue du Rhumatisme (Edition Francaise) 2000; 67(7):486–97.
- [33] Rico H, Roca-Botran C, Hernandez ER, Seco C, Paez E, Valencia MJ, et al. The effect of supplemental copper on osteopenia induced by ovariectomy in rats. Menopause (New York, NY) 2000;7(6):413–6.
- [34] Buck BC, Ulrich R, Taube V, Jacobsen B, Ganter M. Osteopenia as a result of copper deficiency in a dwarf Thuringian forest goat. Tierarztliche Praxis Ausgabe G, Grosstiere/Nutztiere 2012;40(1):45–52.
- [35] Klevay LM. Lack of a recommended dietary allowance for copper may be hazardous to your health. J Am Coll Nutr 1998; 17(4):322-6.
- [36] Chaudhri MA, Kemmler W, Harsch I, Watling RJ. Plasma copper and bone mineral density in osteopenia: an indicator of bone mineral density in osteopenic females. Biol Trace Elem Res 2009;129(1):94–8.
- [37] Zheng J, Mao X, Ling J, He Q, Quan J. Low serum levels of zinc, copper, and iron as risk factors for osteoporosis: a metaanalysis. Biol Trace Elem Res 2014;160(1):15–23.
- [38] Rest JR. The histological effects of copper and zinc on chick embryo skeletal tissues in organ culture. Br J Nutr 1976;36(2): 243-54.
- [39] Massie HR, Aiello VR, Shumway ME, Armstrong T. Calcium, iron, copper, boron, collagen, and density changes in bone with aging in C57BL/6J male mice. Exp Gerontol 1990;25(5): 469-81.
- [40] Li S, Wang M, Chen X, Li SF, Li-Ling J, Xie HQ. Inhibition of osteogenic differentiation of mesenchymal stem cells by copper supplementation. Cell Prolif 2014;47(1):81–90.
- [41] Burghardt I, Lüthen F, Prinz C, Kreikemeyer B, Zietz C, Neumann H-G, et al. A dual function of copper in designing regenerative implants. Biomaterials 2015;44:36-44.
- [42] Dermience M, Lognay G, Mathieu F, Goyens P. Effects of thirty elements on bone metabolism. J Trace Elem Med Biol Organ Soc Miner Trace Elem (GMS) 2015;32:86–106 [eng].
- [43] A A. Trace element nutrition and bone metabolism. Nutr Res Rev 1992;5(1):167–88.
- [44] Goodman SB, Qin L. Inflammation and the musculoskeletal system. J Orthop Translat 2017;10:A1-2.
- [45] Gallo J, Raska M, Kriegova E, Goodman SB. Inflammation and its resolution and the musculoskeletal system. J Orthop Translat 2017;10:52-67.
- [46] Quemeneur AS, Trocello JM, Ea HK, Ostertag A, Leyendecker A, Duclos-Vallee JC, et al. Bone status and fractures in 85 adults with Wilson's disease. Osteoporosis Int 2014;25(11):2573–80.